HomeCompareICPT vs PLD

ICPT vs PLD: Dividend Comparison 2026

ICPT yields 10.53% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.46M in total portfolio value· pulled ahead in Year 4
10 years
ICPT
ICPT
● Live price
10.53%
Share price
$19.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.1K
Annual income
$2,037.15
Full ICPT calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ICPT vs PLD

📍 PLD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICPTPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICPT + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICPT pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICPT
Annual income on $10K today (after 15% tax)
$894.74/yr
After 10yr DRIP, annual income (after tax)
$1,731.58/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,466,239.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICPT + PLD for your $10,000?

ICPT: 50%PLD: 50%
100% PLD50/50100% ICPT
Portfolio after 10yr
$3.27M
Annual income
$2,629,236.66/yr
Blended yield
80.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ICPT
Analyst Ratings
16
Buy
19
Hold
5
Sell
Consensus: Hold
Price Target
$22.11
+16.4% upside vs current
Range: $10.00 — $44.00
Altman Z
-5.0
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICPT buys
0
PLD buys
0
No recent congressional trades found for ICPT or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICPTPLD
Forward yield10.53%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$40.1K$6.50M
Annual income after 10y$2,037.15$5,256,436.18
Total dividends collected$15.4K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$22.11$136.00

Year-by-year: ICPT vs PLD ($10,000, DRIP)

YearICPT PortfolioICPT Income/yrPLD PortfolioPLD Income/yrGap
1$11,753$1,052.63$11,255$555.24+$498.00ICPT
2$13,732$1,156.19$13,062$1,018.59+$670.00ICPT
3$15,955$1,262.49$15,903$1,926.67+$52.00ICPT
4← crossover$18,443$1,370.97$20,839$3,823.32$2.4KPLD
5$21,215$1,481.06$30,464$8,166.08$9.2KPLD
6$24,292$1,592.22$52,054$19,457.30$27.8KPLD
7$27,697$1,703.90$109,886$54,188.93$82.2KPLD
8$31,451$1,815.59$304,030$186,451.18$272.6KPLD
9$35,580$1,926.82$1,166,125$840,813.32$1.13MPLD
10$40,107$2,037.15$6,504,190$5,256,436.18$6.46MPLD

ICPT vs PLD: Complete Analysis 2026

ICPTStock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Full ICPT Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ICPT vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICPT vs SCHDICPT vs JEPIICPT vs OICPT vs KOICPT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.